major depressive disorder
Showing NaN - NaN of 70
MDD Trial in United States (SAGE-217, Placebo)
MDD, Insomnia Trial in United States (SAGE-217, Placebo)
Terminated
- Major Depressive Disorder
- Insomnia
- SAGE-217
- Placebo
-
Little Rock, Arkansas
- +27 more
Oct 13, 2022
MDD, Treatment Resistant Depression, Depression Trial in United States (AXS-05)
Completed
- Major Depressive Disorder
- +2 more
- AXS-05 (dextromethorphan and bupropion) oral tablets
-
Phoenix, Arizona
- +50 more
Sep 16, 2022
Anhedonia, MDD Trial in Puerto Rico, United States (Placebo, NBI-1065846)
Recruiting
- Anhedonia
- Major Depressive Disorder
- Placebo
- NBI-1065846
-
Birmingham, Alabama
- +11 more
Jun 27, 2022
MDD Trial in United States (SP-624, Placebo)
Active, not recruiting
- Major Depressive Disorder
- SP-624
- Placebo
-
Phoenix, Arizona
- +38 more
May 13, 2022
MDD Trial in United States (BTRX-335140, Placebo)
Active, not recruiting
- Major Depressive Disorder
- BTRX-335140
- Placebo
-
Phoenix, Arizona
- +37 more
Mar 11, 2022
MDD Trial in United States (Levomilnacipran ER, Fluoxetine, Placebo)
Completed
- Major Depressive Disorder
- Levomilnacipran ER
- +2 more
-
Little Rock, Arkansas
- +50 more
Mar 1, 2022
Depression, MDD Trial in United States (AXS-05, Placebo)
Completed
- Depression
- Major Depressive Disorder
- AXS-05
- Placebo
-
Phoenix, Arizona
- +42 more
Sep 22, 2021
MDD Trial in Worldwide (SPD489 (Lisdexamfetamine dimesylate) + Antidepressant)
Terminated
- Major Depressive Disorder
- SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
-
Birmingham, Alabama
- +211 more
Jun 9, 2021
MDD Trial in United States (Antidepressant + SPD489 (lisdexamfetamine dimesylate), Antidepressant + )
Completed
- Major Depressive Disorder
- Antidepressant + SPD489 (lisdexamfetamine dimesylate)
- Antidepressant + placebo
-
Newport Beach, California
- +14 more
Jun 8, 2021
MDD Trial in Worldwide (Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Antidepressant + SPD489 (Lisdexamfetamine
Completed
- Major Depressive Disorder
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg
- +4 more
-
Little Rock, Arkansas
- +81 more
May 25, 2021
MDD Trial in United States (CP-601,927, Placebo)
MDD Trial in Australia, Puerto Rico, United States (ALKS 5461, ALKS 5461 Placebo)
Completed
- Major Depressive Disorder
- ALKS 5461
- ALKS 5461 Placebo
-
Tucson, Arizona
- +34 more
Mar 15, 2021
MDD Trial in United States (Vortioxetine, Placebo)
MDD Trial in Puerto Rico, United States (Agomelatine (AGO178C), Placebo)
Completed
- Major Depressive Disorder
- Agomelatine (AGO178C)
- Placebo
-
Birmingham, Alabama
- +44 more
Dec 16, 2020
MDD Trial in Puerto Rico, United States (Agomelatine (AGO178C), Placebo)
Completed
- Major Depressive Disorder
- Agomelatine (AGO178C)
- Placebo
-
Birmingham, Alabama
- +47 more
Dec 15, 2020
MDD Trial in Puerto Rico, United States (Placebo, Levomilnacipran, Fluoxetine)
Completed
- Major Depressive Disorder
- Placebo
- +2 more
-
Dothan, Alabama
- +48 more
Aug 19, 2020
MDD Trial in United States (Assay-guided treatment (AGT), Treatment-as-usual (TAU))
Completed
- Major Depressive Disorder
- Assay-guided treatment (AGT)
- Treatment-as-usual (TAU)
-
Birmingham, Alabama
- +22 more
Aug 27, 2020
MDD Trial in United States (TS-121 10 mg, TS-121 50 mg, Placebo)
Terminated
- Major Depressive Disorder
- TS-121 10 mg
- +2 more
-
Little Rock, Arkansas
- +21 more
Jul 1, 2020